Rex Hudson, MD
General Practice · Saint Louis, MONPI 1235113325
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $46,779 of the $48,766 with a category attached, or 95.9%. Every reported general payment came from a single manufacturer, Novartis. Reporting peaked in 2021 at $19,501 and has fallen 92.1% since, to $1,540 in 2024. Among general practice clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 94 payments — averaging $518.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$49K
What the payments were for
- Consulting fees$46,77996%
- Speaking & faculty fees$9502%
- Travel & lodging$1,0372%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 94 | $48,766 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$48,766 in reported general payments places this provider in the 95th percentile of 1,446 general practice providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 234 | $45,989 |
| XareltoRivaroxaban | 49 | $13,041 |
| TrulicityDulaglutide | 12 | $12,444 |
| LinzessLinaclotide | 17 | $9,302 |
| MyrbetriqMirabegron | 52 | $8,630 |
| JardianceEmpagliflozin | 30 | $7,522 |
| Famotidine | 89 | $6,687 |
| JanuviaSitagliptin Phosphate | 30 | $4,321 |
| FarxigaDapagliflozin Propanediol | 21 | $3,966 |
| LumiganBimatoprost | 14 | $3,773 |
| TradjentaLinagliptin | 20 | $3,565 |
| Breo ElliptaFluticasone/Vilanterol | 21 | $3,469 |
| Levothyroxine Sodium | 455 | $3,293 |
| Mirtazapine | 214 | $2,492 |
| Atorvastatin Calcium | 281 | $2,308 |
Paid to pharmacies, not to this prescriber.
Other general practice in Saint Louis
- Nadeemuddin QureshiSaint Louis$22K
- Sable MunteanSaint Louis$16K
- Johnathan MillerSaint Louis$13K
- Jason AllenSaint Louis$11K
- Jeffrey SindelarSaint Louis$9K
- William WhitsonSaint Louis$6K
- Mark HeskerSaint Louis$5K
- Michael TravisSaint Louis$5K
- Seth WassonSaint Louis$5K
- Jeremy PfefferSaint Louis$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.